Ordering Recommendation

Acceptable reflexive panel for diagnosing myasthenia gravis. Includes acetylocholine receptor (AChR) binding and blocking antibodies, titin anibodies, and striated muscle antibodies, with possible reflex to AChR modulating antibodies or striated muscle antibody titer.

Mnemonic
MGT R PAN
Methodology

Quantitative Radioimmunoassay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Flow Cytometry

Performed

Mon-Fri

Reported

1-8 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Plain red top or Serum Separator Tube (SST).

Specimen Preparation

Transport 1.5 mL serum. (Min. 0.7 mL) Separate serum from cells ASAP or within one hour of collection. Transfer to an ARUP Standard Transport Tube.

Storage/Transport Temperature

Refrigerated. Frozen is also acceptable. 

Unacceptable Conditions

Plasma. Hemolyzed, lipemic, moderately icteric serum or contaminated specimens.

Remarks

Repeated freeze-thaw cycles should be avoided.

Stability

Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year

Reference Interval
Test Number
Components
Reference Interval
0080009 Acetylcholine Receptor Binding Antibody
Negative 0.0-0.4 nmol/L
Positive 0.5 nmol/L or greater

0099580 Acetylcholine Receptor Blocking Antibody Effective November 18, 2013
Negative: 0-26% blocking
Indeterminate: 27-41% blocking
Positive: 42% or greater blocking

0099521 Acetylcholine Receptor Modulating Antibody Effective August 20, 2012
Negative 0-45% modulating
Positive 46% or greater modulating

2005636 Titin Antibody Effective January 17, 2012
Titin Antibody
Negative 0.00-0.45 IV
Indeterminate 0.46-0.71 IV
Positive 0.72 IV or greater

0050746 Striated Muscle Antibodies, IgG with Reflex to Titer Less than 1:40

Interpretive Data

Refer to report.

Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.

Note

If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody will be added. If Striated Muscle Ab is detected, then a titer will be added. Additional charges apply.

Hotline History
N/A
CPT Codes

83519; 83516 x2; 86255;  if reflexed, add 83516 and/or 86256

Components
Component Test Code* Component Chart Name LOINC
0050747 Striated Muscle Antibodies, IgG Screen 49692-7
0080009 Acetylcholine Binding Antibody 11034-6
0099580 Acetylcholine Blocking Antibody 42937-3
2005637 Titin Antibody
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • AChR Binding Antibody
  • AChR Antibody
  • Anti-Skeletal Muscle IgG Antibodies
  • Anti-Striated Antibody
  • anti-tintin Ab
  • Muscle (Skeletal) Antibodies
  • Muscle nicotinic Acetylcholine Receptor
  • Myasthenia Gravis Antibodies
  • Myoid Antibody
  • Skeletal Muscle Antibodies
  • Striational Antibodies
Acetylcholine Receptor Antibodies and Striated Muscle Antibodies Reflexive Panels, and Titin Antibody